BioNTech SE
Q2 2022 Earnings Call
Aug 08, 2022, 8:00 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Welcome to the BioNTech second quarter 2022 update call. I would like to hand the call over to the vice president of investor relations and strategy, Sylke Maas. Please go ahead, Sylke.
Sylke Maas -- Vice President, Investor Relations
Good morning, and good afternoon. Thank you for joining us today to review BioNTech's second quarter '22 clinical and declaration of progress and financial results. A few housekeeping items before we start. I invite you to view the slides that accompany the webcast and the second quarter 2022 press release, both of which were issued this morning and can be found in the investors section of our website.
As outlined on Slide 2, during today's presentation, we will be making several forward-looking statements. These forward-looking statements include, but are not limited to our current COVID-19 vaccine revenues as these include figures that are derived from preliminary estimates provided by our partners; our estimated financial results for 2022; the continued global demand for our COVID-19 vaccine; our target vaccine production capacity for 2022 and beyond; our ability to supply our COVID-19 vaccine; the plan next steps in our pipeline programs; the timing for enrollment initiation, completion and reporting of data from all clinical trials; the timing of our ability to obtain and maintain regulatory approval for our product candidates and other risks described in our filings made with the U.S. Securities and Exchange Commission, including our most recent annual report filed today. Actual results could differ from those we currently anticipate.
You are therefore cautioned not to place undue reliance on any forward-looking statements, which speak only as of today, shared today during this conference call and webcast. Also, please note that Slide 3, 4, and 5 provides details on the important safety information regarding our COVID-19 vaccine. Finally, you can find the agenda for today's call on Slide 6. It's my pleasure to introduce the members of BioNTech's management team participating in today's call.
I'm joined today by our CEO, co-founder, Uğur Şahin; Ozlem Tureci, our chief medical officer and co-founder; Jens Holstein, our chief financial officer; and Ryan Richardson, our chief strategy officer. I would like to turn the call over to Uğur Şahin.